Metachronous Double Primary Cancer after Treatment of Breast Cancer

Jin Young Kim; Hong Suk Song

doi:10.4143/crt.2013.215

Articles

Page Path: HOME > Cancer Res Treat > Volume 47(1); 2015 > Article

Original Article Metachronous Double Primary Cancer after Treatment of Breast Cancer: Jin Young Kim, MD, Hong Suk Song, MD; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2015;47(1):64-71.
DOI: https://doi.org/10.4143/crt.2013.215
Published online: October 27, 2014

Division of Hemato-Oncology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea

Correspondence: Hong Suk Song, MD Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, 56 Dalseong-ro, Jung-gu, Daegu 700-712, Korea
Tel: 82-53-250-7436 Fax: 82-53-425-6476 E-mail: shs7436@dsmc.or.kr

• Received: October 24, 2013 • Accepted: December 18, 2013

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

14,490 Views
120 Download
24 Web of Science
16 Crossref
25 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
The pattern of double primary cancer after treatment for breast cancer is important for patient survival.
Materials and Methods
We analyzed 108 cases of metachronous double primary cancer in breast cancer patients treated from 1999 to 2012.
Results
Metachronous double primary cancers occurred in 108 of 2,657 patients (4.1%) with breast cancer. The median time to the occurrence of second cancer after diagnosis of the first was 58.4±41.2 months (range, 6.9 to 180.2 months). The most common cancer was thyroid cancer, which occurred in 45 patients (41.7%). This was followed by gastric cancer in 16 patients (14.8%), endometrial cancer in 10 patients (9.3%), and cervical cancer in seven patients (6.5%). The relative risk showed a significant increase in endometrial (4.78; 95% confidence interval [CI], 1.66 to 13.79), gastric (2.61; 95% CI, 1.68 to 4.06), and thyroid cancer (1.95; 95% CI, 1.37 to 2.79). At 5 years after diagnosis of breast cancer, secondary cancer occurred in 48 patients (44.4%), with 50.0% of the endometrial, 56.3% of the stomach, and 37.8% of the thyroid cancer cases being diagnosed after 5 years. Median survival after diagnosis of the second cancer was 123.9±11.2 months. The prognosis was mainly influenced by the anatomic site.
Conclusion
The incidence of endometrial, stomach, and thyroid cancer increased significantly after treatment with primary breast cancer, and survival was dependent on early detection and the type of second primary cancer. A prolonged follow-up examination for metachronous double primary cancer is needed to provide early detection and improve survival time in patients with breast cancer.
Key words: Breast neoplasms, Second primary neoplasms, Diagnosis

Introduction

The incidence of breast cancer is increasing in Korea, and it is now the second most common cancer in women, with an age adjusted incidence rate in 2010 of 45.4 [1]. This increase in breast cancer incidence is partly attributed to improved screening and diagnostic techniques, as well as changes in reproductive patterns, specifically, women waiting until later to have children [2]. In Korea, cancer screening rates have shown a significant increase from 2004 to 2012, and screening rates for breast cancers are now approaching 70% [3].

Through achievement of remarkable advances in cancer treatment and early detection of cancer, the number of patients who survive cancer has shown a significant increase. Grundmann and Meyer [4] suggested that rising population age and advances in treatment with improved survival from cancer have led to more frequent survival of cancer treatment and subsequently more patients with a second primary tumor. The reasons for these changes may be environmental modifications, genetic predisposition, therapy, or increased surveillance.

The criteria for diagnosing multiple primary tumors are 1) each tumor must present a definite picture of malignancy; 2) each must be distinct; and 3) the probability that one was a metastatic lesion originating from the other must be excluded. Patients with metachronous cancer are defined as those diagnosed with a secondary cancer six months or more after their primary diagnosis with breast cancer.

Although there have been numerous reports of metachronous cancers among breast cancer patients, most are from Western countries and in case report form. Additionally, the incidence of metachronous cancer varies to the extent that the clinical results differ in each study, and the general pattern of metachronous breast cancer still needs to be clarified. Further characterization of metachronous breast cancer could provide valuable information for use in early diagnosis and treatment of these diseases. Awareness, suspicion of multiple primary malignancy and aggressive diagnostic work ups play crucial roles in detection of cancer in earlier stages and can result in a better outcome.

This study was designed to evaluate the relative risk (RR) of developing additional cancers at different sites and the prognosis of metachronous breast cancer in Korea.

Materials and Methods

Between March 1994 and July 2012, 2,657 patients underwent surgical treatment or chemotherapy for breast cancer at Keimyung University Dongsan Medical Center, excluding those receiving treatment for breast lymphoma. Patients who were diagnosed with new primary cancer developing from other organs were selected from the original group. Among the 2,657 patients who underwent treatment for breast cancer, metachronous cancers were diagnosed in 108 patients over a period of 18 years. Patients with metachronous cancer are defined as those with an interval of six months or more after their initial diagnosis of breast cancer. All patients with breast cancer were histologically diagnosed by core needle or surgical biopsy. Second primary cancer was confirmed by histological diagnosis; however, hepatocellular carcinoma was confirmed in two cases by imaging and a tumor marker study. Therefore, it is unlikely that any metastasis was mistaken as a second primary cancer. The age of the patients at the onset of metachronous cancer or in the TNM stage according to the sixth edition of the American Joint Committee on Cancer (AJCC), and the presence of factors that could mediate effects on survival rate were examined retrospectively. Evaluation of the interval from the first pathologic diagnosis of breast cancer to the development of a second primary cancer, clinical characteristics, and survival rate after diagnosis of a second cancer was based on medical records.

The control population was extracted from data provided by the Korean Central Cancer Registry and the National Cancer Center operated by the Ministry of Health and Welfare.

1. Statistical analysis

The yearly incidence (per 100,000) of the various malignancies in both the control and breast cancer were compared. The ratio of these two values and 95% confidence intervals indicated the RR coefficient of having cancer.

The Kaplan-Meier method was used for generation of overall survival curves. The survival curve for patients with metachronous double primary cancer was calculated from the date of diagnosis of the second cancer. Analyses were conducted using SPSS ver. 18.0 (SPSS Inc., Chicago, IL).

Results

Among 2,657 patients with breast cancer, 108 (4.1%) were diagnosed with metachronous double primary cancer. In a comparison of the sex distribution of the patients, double primary cancer occurred more frequently in males but was not statistically different. Double primary cancer occurred in one of 15 males (6.7%) and 107 of 2,642 female (4.2%) patients (p=0.464). As shown in Table 1, age distribution between groups did not differ (p=0.053). The most common age group included patients aged 40 to 50, and the most common metachronous double primary cancer was thyroid cancer, followed by stomach, endometrium, cervix, and lung cancers.

Table 2 shows the median age distribution of patients with metachronous double primary cancer. A significant difference was observed among the types of metachronous double primary cancers (p < 0.001), and the median age was 55.9±10.3 years. Hepatocellular cell carcinoma had the oldest median age of 73.8 years, while nasopharyngeal cancer had the youngest age of 39.5 years.

Table 3 shows the yearly diagnostic period of metachronous double primary cancer and does not indicate any notable difference in incidence from year to year. The mean diagnostic period was 58.4±41.2 months, and no significant differences were observed among cancer types (p=0.157). Acute leukemia, thyroid, colorectal, and biliary cancers were diagnosed earlier than other cancers (Table 4).

The occurrence of a double primary cancer within 5 years of the initial diagnosis of breast cancer was evident in 60 patients (55.6%). Ten years after the initial diagnosis of breast cancer, 10 patients (9.3%) were diagnosed with double primary cancer. These cases included stomach cancer in two patients, lung cancer in two patients and thyroid, cervical, rectal, colon, liver, and bladder cancer in one patient each. The development of hepatocellular carcinoma (50.0%), bladder cancer (50.0%), and lung cancer (40.0%) occurred much more frequently in 10 years after the diagnosis of breast cancer (Table 5).

Table 6 shows the RR of metachronous double primary cancer in breast cancer. The RR was higher for nasopharyngeal (6.30), endometrial (4.78), acute myelogenous leukemia (2.61), stomach (2.61), bladder (2.37), and thyroid cancer (1.95) with primary breast cancer, but only endometrial, gastric and thyroid cancer were statistically significant.

The mean follow-up period was 45.9 months for metachronous cancers. The mean survival time of metachronous double primary cancer was 169.1±9.8 months (95% confidence interval [CI], 149.8 to 188.3 months) (Fig. 1). The 5-year survival rate and median survival of metachronous cancer in breast cancer patients was 72.3% and 123.9±11.2 months, respectively. The 5-year survival rates after diagnosis of second cancer were 100% for thyroid and colon cancer, 83.3% for cervical cancer, 80.0% for endometrial cancer, 66.7% for rectal cancer, 61.9% for stomach cancer, 22.2% for lung cancer, and 0% for liver, biliary, ovarian cancer and acute leukemia, and these values differed significantly according to cancer type (p < 0.001) (Table 7). The median survival period for patients with endometrial, cervical, and colorectal cancers was similar to or longer than that of other cancers.

Discussion

Multiple primary cancers seem to be increasing in frequency, but various quantitative differences have been observed. For example, cancer patients in Connecticut had a 31% higher risk of developing a subsequent cancer [5], whereas no excessive risk was observed in Denmark [6] or Finland [7]. Differences in study methodology may explain these apparent discrepancies in part, but it is possible that they are due to common genetic susceptibility and environmental factors such as etiological aspects (e.g., for smoking or diet-related cancers) and/or different consequences of cancer treatment in various populations.

In this study, the incidence of second primary cancer was 4.1% and the RR of all cancer in breast cancer was 0.95. This figure appears to be underestimated, as patients who had not been diagnosed with pathologic confirmation due to their physical condition and/or having difficulty in receiving a pathologic diagnosis were excluded. It should be noted that this study had a relatively limited study population size and excluded secondary breast cancer patients, which likely led to underestimation of the total incidence of patients with a second primary cancer. In another Korean study [8], the incidence rate of metachronous cancer was 34 in 7,735 breast cancer patients (0.4%), which was unusually low when compared with present hospita l-based cancer registry studies. Raymond and Hogue [2] found that 12.3% of breast cancer survivors were diagnosed with second primary malignant tumors, while Schenker et al. [9] found that figure to be 8% in a similar study. Mellemkjaer et al. [10] found a standardized incidence rate (SIR) of total metachronous primary cancer in breast cancer of 1.25, while the SIR was 1.2 and 1.7 for total metachronous cancer and second breast cancer, respectively, in the Swiss Vaud Cancer Registry [11]. These findings suggest that second breast cancer is a high component of second primary cancer. However, Stracci et al. [12] investigated data from the Umbrian Population Cancer Registry (RTUP) and found that the SIR was non-significant, including that for metachronous contralateral breast cancer.

In this study, the most common second double primary cancer was thyroid cancer, followed by stomach, endometrial, cervical, and lung cancers. The statistically significant cancers were endometrial cancer (RR, 4.78), stomach cancer (RR, 2.61), and thyroid cancer (RR 1.95). Breast cancer survivors had the greatest risk for developing breast, bone, colon/rectal, connective tissue (sarcoma), leukemia, lung, ovary, or thyroid cancer [2]. Schenker et al. [9] demonstrated that the most common second primary cancer in breast cancer patients was that of the opposite breast (23.9%), and that the diagnosis of second breast cancer was made an average of 7 years after the first cancer was detected. Their study also revealed that the likelihood of developing uterine corpus, thyroid and ovarian cancer was greater than in the general population, while stomach and gall bladder cancer had relatively low risks (0.5 and 0.3, respectively). Mellemkjaer et al. [10] found the following SIR rates for second cancer: stomach 1.35, colorectal 1.22, lung 1.24, soft tissue sarcoma 2.25, melanoma 1.29, non-melanoma skin 1.58, endometrium 1.52, ovary 1.48, kidney 1.27, thyroid 1.62, and leukemia 1.52. In the Swiss Vaud Cancer registry, the SIR was 2.2 for thyroid cancer, 1.4 for pancreas cancer, 1.2 for uterine corpus cancer, and 1.1 in colorectal cancer [11]. Stracci et al. [12] reported an increased occurrence of salivary gland, uterine corpus, ovarian and thyroid cancer, as well as a significant excess of melanoma and second breast cancers. The excessive skin melanoma in breast cancer survivors was attributed to the relationship with BRCA2 and CDKN2A mutation-positive patients. Parikh and Advani [13] conducted a study in India that revealed the most prevalent second tumor to be ovarian cancer, and that second cancer patients have worse survival rates than breast cancer patients without second cancer. The incidence of metachronous second cancer varies among studies, and the discrepancies in the type of second cancer is influenced by several factors including race, hormone status, environment, and genetic disposition. Studies have provided consistent findings in terms of excesses of various cancer sites for cancer of the endometrium [7,10,14], thyroid cancer [2,7,9-12,14,15], and ovarian cancer [2,9,10,12,13,16,17]. Breast, ovary, and endometrial cancers may have a common etiology, with high fat diet, effect of sex hormone levels, and reduced fertility being candidate factors [9].

The mean diagnostic period of second primary cancer was 58.4±41.2 months, while it was 46.4 months in another Korean study [4]. The diagnostic period showed no significant differences among cancer types (p=0.157). Acute leukemia, thyroid, colorectal and biliary cancers were diagnosed earlier than other cancers (Table 4). Five years after the initial diagnosis of breast cancer, a second primary cancer was diagnosed in 48 patients (44.4%). After 10 years, 10 patients (9.3%) were diagnosed with a double primary cancer. Clinicians previously believed that being cancer free for 5 years after the initial diagnosis indicated that the patient was cured of cancer, and the results of the present study indicate that a considerable proportion of women who developed a second cancer were cancer-free 5 years after their initial diagnosis.

Of all patients who developed a second primary cancer following cancer of the breast, a significantly high rate of previous radiotherapy was only found in those with lung cancer (82%) and cancer of the hematopoietic system (95%) [9]. The cancer types of concern with respect to radiotherapy are those in organs close to the breast, such as the esophagus, lung, thyroid gland, stomach, soft tissue sarcoma of the thorax and upper limb and leukemia [7]. Thyroid cancer is regarded as a radiation inducible cancer, as excess cancer of the thyroid is not treatment induced [10]. Grundmann and Meyer [4] proposed that radiotherapy increases the rate of second primary neoplasm, and that adjuvant radiotherapy should be well justified. Nevertheless, this is true only for young patients, mainly in childhood, and the risk of a second cancer after irradiation in adults is small. In this study, radiation treatment was only administered to 37.8% of second thyroid cancer patients.

Tamoxifen may be associated with endometrial proliferation, hyperplasia, polyp formation, invasive carcinoma, and uterine sarcoma. An increased risk of endometrial cancer has been observed in prevention and adjuvant trials of tamoxifen [18]. Mellemkjaer et al. [10] suggested that excess endometrial cancer was not entirely caused by tamoxifen. Thus, common risk factors such as reproductive and genetic factors, obesity, and/or some unknown factors are likely responsible for some of this excess. Any symptoms of endometrial hyperplasia or cancer reported by postmenopausal women taking tamoxifen should be evaluated. Premenopausal women treated with tamoxifen have no known increased risk of uterine cancer, and therefore require no additional monitoring beyond routine gynecologic care. If a typical endometrial hyperplasia develops, appropriate gynecologic management should be instituted, and the use of tamoxifen should be reassessed. The American Society of Clinical Oncology (ASCO) Panel recommends that women with intact uteri who are taking adjuvant tamoxifen have annual gynecologic assessments and undergo rapid evaluation of any vaginal spotting that might occur because of the risk of tamoxifen-associated endometrial carcinoma in postmenopausal women [19]. However, routine endometrial biopsy or ultrasonography of asymptomatic women is not recommended because the vast majority of women with tamoxifen-associated uterine carcinoma have early vaginal spotting [19]. In this study, 10 endometrial cancer patients received tamoxifen, and vaginal spotting was observed in 30% of those diagnosed in the early stage through regular, periodic gynecologic examination. The 5-year survival rate found in the study (80.0%) was similar to that of the occurrence in the general population (86.2%).

In this study, the 5-year survival and median survival rates of metachronous cancer in breast cancer patients were 72.3% and 123.9±11.2 months, respectively. This study also found significantly different 5-year survival rates after the diagnosis of second cancer of 100%, 83.3%, 80.0%, 66.7%, and 61.9% in thyroid and colon, cervical, endometrial, rectal, and stomach cancer patients, respectively (p < 0.001). Endometrial, cervical and colon cancers had a high median survival due to early detection through annual periodic examination. In general, overall survival was poorer for women with multiple primary tumors than women with no second tumors [2], and cancers known to be associated with low survival rates when appearing on their own have the same effect when they occur in breast cancer patients [9]. The prognosis of breast cancer patients with multiple primary tumors depends on the type of the second primary tumor, its malignancy, and its response to treatment.

Conclusion

In the present study, metachronous double primary cancers were found in 108 of 2,657 breast cancer patients (4.1%), and the RR showed a significant increase in endometrial, stomach and thyroid cancer. The survival rate of second primary cancer was much higher for endometrial and cervical cancer, possibly due to the earlier detection of this type of cancer. A prolonged follow-up examination for metachronous double primary cancer is needed to provide earlier detection and subsequent improvement in the length of survival for patients with breast cancer.

NOTES

Conflict of interest relevant to this article was not reported.

Fig. 1.

Kaplan-Meier survival curve of metachronous double primary cancer of breast cancer patients from the diagnosis of second cancer (n=108).

Table 1.

Sex and age distribution at the time of diagnosis of breast cancer with or without second primary cancer

Age (yr)	With second cancer		Without second cancer
Age (yr)	Male	Female	Male	Female
11-20	-	-	0	3 (0.1)
21-30	-	-	0	61 (2.4)
31-40	0	6 (5.6)	1 (7.1)	354 (14.0)
41-50	0	43 (40.2)	1 (7.1)	914 (36.1)
51-60	0	35 (32.7)	4 (28.6)	675 (26.6)
61-70	1	16 (15.0)	6 (42.9)	360 (14.2)
71-80	0	6 (5.6)	2 (14.3)	144 (5.7)
81-90	0	1 (0.9)	0	24 (0.9)
Total	1	107	14	2,535

Values are presented as number (%).

Table 2.

Cancer type and mean age distribution of metachronous double primary cancer in breast cancer patients

Cancer type	Double primary cancer
Cancer type	No.	Age (yr)
Thyroid cancer	45 (41.7)	52.0±7.3 (41.6-73.9)
Stomach cancer	16 (14.8)	65.4±4.7 (46.8-74.3)
Endometrial cancer	10 (9.3)	55.3±13.6 (39.3-83.3)
Cervical cancer	7 (6.5)	48.9±15.7 (35.0-72.6)
Lung cancer	5 (4.6)	65.0±5.3 (58.4-72.1)
Rectal cancer	4 (3.7)	60.7±12.3 (44.6-74.6)
Acute myelocytic leukemia	4 (3.7)	50.0±6.3 (48.1-61.8)
Colon cancer	3 (2.8)	65.4±4.7 (59.0-68.1)
Biliary cancer	3 (2.8)	68.7±12.8 (60.5-85.7)
Ovarian cancer	3 (2.8)	57.3±3.3 (54.4-61.0)
Hepatocellular carcinoma	2 (1.9)	73.8±3.3 (71.5-76.2)
Bladder cancer	2 (1.9)	69.3±11.8 (61.0-77.6)
Nasopharyngeal cancer	1 (0.9)	39.5
Renal cell carcinoma	1 (0.9)	49.5
Acute lymphocytic leukemia	1 (0.9)	48.2
Total	108	55.9±10.3 (35.0-85.7)

Values are presented as number (%) or mean±standard deviation (range).

Table 3.

Diagnostic period of metachronous double primary cancer in patients with breast cancer

Diagnostic period (yr)	No.
< 1	13
1-3	28
3-5	19
5-7	14
7-9	21
9-1	9
11-13	2
13-15	1
15-17	1
Total	108

Values are presented as number (%).

Table 4.

Mean diagnostic period of metachronous double primary cancer in breast cancer patients

Cancer type	Diagnostic period (mo)
Thyroid cancer	48.9±33.9 (7.1-121.8)
Stomach cancer	71.5±41.5 (6.9-129.3)
Endometrial cancer	60.5±37.4 (8.5-107.9)
Cervical cancer	61.3±60.9 (8.5-180.2)
Lung cancer	89.1±45.9 (21.9-142.3)
Rectal cancer	53.1±58.4 (8.3-135.2)
Acute myelocytic leukemia	21.1±11.0 (11.0-36.3)
Colon cancer	51.9±63.2 (9.5-124.5)
Biliary cancer	51.3±29.5 (24.2-82.7)
Ovarian cancer	56.5±38.4 (13.2-90.4)
Hepatocellular carcinoma	86.4±49.4 (51.5-121.3)
Bladder cancer	129.65±45.5 (97.5-161.8)
Nasopharyngeal cancer	69.7
Renal cell carcinoma	84.7
Acute lymphocytic leukemia	26.4
Total	58.4±41.2 (6.9-180.2)

Values are presented as mean±standard deviation (range).

Table 5.

Diagnosis of metachronous double primary cancer 5 years and 10 years after diagnosis of breast cancer

Cancer type	After 5 years	After 10 years	Total
Thyroid cancer	17 (37.8)	1 (2.2)	45
Stomach cancer	9 (56.3)	2 (12.5)	6
Endometrial cancer	5 (50.0)	-	10
Cervical cancer	3 (42.9)	1 (14.3)	7
Lung cancer	4 (80.0)	2 (40.0)	5
Rectal cancer	1 (25.0)	1 (25.0)	4
Acute myelocytic leukemia	-	-	4
Colon cancer	1 (33.3)	1 (33.3)	3
Biliary cancer	1 (33.3)	-	3
Ovarian cancer	2 (66.7)	-	3
Hepatocellular carcinoma	1 (50.0)	1 (50.0)	2
Bladder cancer	2 (100)	1 (50.0)	2
Nasopharyngeal cancer	1 (100)	-	1
Renal cell carcinoma	1 (100)	-	1
Acute lymphocytic leukemia	-	-	1
Total	48 (44.4)	10 (9.3)	108

Values are presented as number (%).

Table 6.

Relative risk of metachronous double primary cancer in breast cancer patients

Cancer type	Relative risk	95% CI
Nasopharyngeal cancer	6.30	0.15-271.59
Endometrial cancer	4.78	1.66-13.79
Acute myelocytic leukemia	2.61	0.70-9.81
Stomach cancer	2.61	1.68-4.06
Bladder cancer	2.37	0.39-14.40
Thyroid cancer	1.95	1.37-2.79
Ovarian cancer	1.05	0.33-3.34
Biliary cancer	1.04	0.33-3.28
Cervical cancer	0.94	0.45-1.95
Acute lymphocytic leukemia	0.88	0.13-5.94
Lung cancer	0.87	0.40-1.91
Renal cell carcinoma	0.81	0.12-5.24
Rectal cancer	0.55	0.23-1.32
Colon cancer	0.35	0.14-0.90
Hepatocellular carcinoma	0.34	0.11-1.08
Total	0.95	0.79-1.15

CI, confidence interval.

Table 7.

Median survival after diagnosis of metachronous double primary cancer in patients with breast cancer

Cancer type	No.	5-Year survival rate (%)^a)	Median±SD (mo)	95% CI
Thyroid cancer	45	100	-	-
Stomach cancer	16	61.9	64.4±12.4	40.2-88.7
Endometrial cancer	10	80.0	150.3±22.8	105.6-195.0
Cervical cancer	7	83.3	128.4±29.8	69.9-186.9
Lung cancer	5	22.2	18.0±4.4	9.3-26.7
Rectal cancer	4	66.7	85.9±26.8	33.5-138.4
Acute myelocytic leukemia	4	0	3.2±1.6	0.1-6.3
Colon cancer	3	100	121.4	-
Biliary cancer	3	0	14.8±6.1	2.9-26.7
Ovarian cancer	3	0	36.6±10.9	15.3-57.9
Hepatocellular carcinoma	2	0	10.4±3.8	3.0-17.8
Bladder cancer	2	-	6.8	-
Nasopharyngeal cancer	1	-	-	-
Renal cell carcinoma	1	-	-	-
Acute lymphocytic leukemia	1	0	-	-
Total	108	72.3	123.9±11.2	102.0-145.9

SD, standard deviation; CI, confidence interval.

^a) 5-Year survival after diagnosis of second cancer.

REFERENCES

1. National Cancer Information Center. 2010 Annual report of the Korea Central Cancer Registry. Korean cancer information center [Internet]. Goyang: National Cancer Information Center; 2012. [cited 2014 Sep 1]. Available from: http://www.cancer.go.kr
2. Raymond JS, Hogue CJ. Multiple primary tumours in women following breast cancer, 1973-2000. Br J Cancer. 2006;94:1745–50. Article PubMed PMC
3. Suh M, Choi KS, Lee YY, Jun JK. Trends in cancer screening rates among Korean men and women: results from the Korean National Cancer Screening Survey, 2004-2012. Cancer Res Treat. 2013;45:86–94. Article PubMed PMC PDF
4. Grundmann RT, Meyer F. Second primary malignancy among cancer survivors: epidemiology, prognosis and clinical relevance. Zentralbl Chir. 2012;137:565–74. Article PubMed
5. Curtis RE, Boice JD Jr, Kleinerman RA, Flannery JT, Fraumeni JF Jr. Summary: multiple primary cancers in Connecticut, 1935-82. Natl Cancer Inst Monogr. 1985;68:219–42. Article PubMed
6. Storm HH, Jensen OM, Ewertz M, Lynge E, Olsen JH, Schou G, et al. Summary: multiple primary cancers in Denmark, 1943-80. Natl Cancer Inst Monogr. 1985;68:411–30. PubMed
7. Teppo L, Pukkala E, Saxen E. Multiple cancer: an epidemiologic exercise in Finland. J Natl Cancer Inst. 1985;75:207–17. PubMed
8. Jung SH, Kwak SS, Kim SC, Park MK, Lee GS, Kim HJ, et al. Clinical characteristics of multiple primary cancer in breast cancer patients. J Breast Cancer. 2007;10:263–8. Article
9. Schenker JG, Levinsky R, Ohel G. Multiple primary malignant neoplasms in breast cancer patients in Israel. Cancer. 1984;54:145–50. Article PubMed
10. Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118:2285–92. Article PubMed
11. Levi F, Randimbison L, Te VC, Rolland-Portal I, Franceschi S, La Vecchia C. Multiple primary cancers in the Vaud Cancer Registry, Switzerland, 1974-89. Br J Cancer. 1993;67:391–5. Article PubMed PMC
12. Stracci F, D'Alo D, Cassetti T, Scheibel M, La Rosa F. Incidence of multiple primary malignancies in women diagnosed with breast cancer. Eur J Gynaecol Oncol. 2009;30:661–3. PubMed
13. Parikh B, Advani S. Pattern of second primary neoplasms following breast cancer. J Surg Oncol. 1996;63:179–82. Article PubMed
14. Volk N, Pompe-Kirn V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control. 1997;8:764–70. Article PubMed
15. Murakami R, Hiyama T, Hanai A, Fujimoto I. Second primary cancers following female breast cancer in Osaka, Japan: a population-based cohort study. Jpn J Clin Oncol. 1987;17:293–302. PubMed
16. Newell GR, Rawlings W, Krementz ET, Roberts JD. Multiple primary neoplasms in blacks compared to whites. 3. Initial cancers of the female breast and uterus. J Natl Cancer Inst. 1974;53:369–73. Article PubMed
17. Schoenberg BS, Greenberg RA, Eisenberg H. Occurrence of certain multiple primary cancers in females. J Natl Cancer Inst. 1969;43:15–32. Article PubMed
18. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300. Article PubMed
19. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol. 2006;107:1475–8. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Deciphering the Patterns of Dual Primary Cases Registered at the Hospital-Based Cancer Registry: First Experience from Rural Cancer Center in North India
Sankalp Sancheti, Alok Kumar Goel, Anshul Singla, Kuldeep Singh Chauhan, Kiran Arora, Debashish Chaudhary, Tapas Dora, Shweta Tahlan, Prithviraj Kadam, Prachi Joshi, Akash Sali, Rahatdeep Singh Brar, Atul Budukh, Ashish Gulia, Jigeeshu Vasishtha Divatia,
Journal of Laboratory Physicians.2023; 15(04): 524. CrossRef
Multiple synchronous primary malignant neoplasms: A case report and literature review
Linlin Hao, Lihui Zhang, Chuanjie Xu, Min Jiang, Geyi Zhu, Jie Guo
Oncology Letters.2023;[Epub] CrossRef
Association between Thyroid Cancer and Breast Cancer: Two Longitudinal Follow-Up Studies Using a National Health Screening Cohort
Young Ju Jin, Mi Jung Kwon, Ji Hee Kim, Joo-Hee Kim, Hyo Geun Choi
Journal of Personalized Medicine.2022; 12(2): 133. CrossRef
Simultaneous gastric cancer and breast cancer metastases to the stomach with lymph node collision tumor: a case report
Takeshi Okamoto, Hidekazu Suzuki, Katsuyuki Fukuda
BMC Gastroenterology.2021;[Epub] CrossRef
Pioneering BRCA1/2 Point-Of-Care Testing for Integration of Germline and Tumor Genetics in Breast Cancer Risk Management: A Vision for the Future of Translational Pharmacogenomics
Lwando Mampunye, Nerina C. van der Merwe, Kathleen A. Grant, Armand V. Peeters, Rispah Torrorey-Sawe, David J. French, Kelebogile E. Moremi, Martin Kidd, Petrus C. van Eeden, Fredrieka M. Pienaar, Maritha J. Kotze
Frontiers in Oncology.2021;[Epub] CrossRef
The Pattern of Second Primary Tumours in Postmenopausal Women with Prior Breast Cancer in Western Romania: A Retrospective, Single-Institution Study
Cristina Marinela Oprean, Larisa Maria Badau, Robert-Alexandru Han, Teodora Hoinoiu, Gabriel-Mugur Dragomir, Daciana Grujic, Tiberiu Dragomir, Alis Dema
Diagnostics.2021; 11(11): 1957. CrossRef
High Incidence and Prevalence of Papillary Thyroid Cancer in Breast Cancer Patients
Jung Ho Park, Sanghwa Kim, Lee Su Kim
Journal of Endocrine Surgery.2020; 20(4): 88. CrossRef
Gastric Complications after Adjuvant Radiotherapy for Breast Cancer
Won Kyung Cho, Doo Ho Choi, Won Park, Haeyoung Kim, Seonwoo Kim, Myung-Hee Shin, Hyejung Cha
Journal of Breast Cancer.2019; 22(3): 464. CrossRef
Clinical Characteristics and Prognosis Associated with Multiple Primary Cancers in Breast Cancer Patients
Bong Kyun Kim, Se Jeong Oh, Jeong-Yoon Song, Han-Byoel Lee, Min Ho Park, Yongsik Jung, Woo-Chan Park, Jina Lee, Woo Young Sun
Journal of Breast Cancer.2018; 21(1): 62. CrossRef
Detection of the early phase of esophageal cancer progression into lamina propria mucosae by the serum p53 antibody
Fumi Saito, Hideaki Shimada, Hideaki Ogata, Takafumi Otsuka, Tetsuo Nemoto, Kazutoshi Shibuya, Hironori Kaneko
Esophagus.2017; 14(4): 366. CrossRef
Metachronous double primary cancer of epithelial and mesenchymal origins
Hongzeng Wu, Ze Li, Helin Feng, Jinming Zhang
Medicine.2017; 96(49): e9036. CrossRef
Development of second primary cancer in Korean breast cancer survivors
Hong Kyu Jung, Suyeon Park, Nam Won Kim, Jong Eun Lee, Zisun Kim, Sun Wook Han, Sung Mo Hur, Sung Young Kim, Cheol Wan Lim, Min Hyuk Lee, Jihyoun Lee
Annals of Surgical Treatment and Research.2017; 93(6): 287. CrossRef
Multiple primary tumours: challenges and approaches, a review
Alexia Vogt, Sabine Schmid, Karl Heinimann, Harald Frick, Christian Herrmann, Thomas Cerny, Aurelius Omlin
ESMO Open.2017; 2(2): e000172. CrossRef
Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer
Li Zhang, Yansheng Wu, Fangfang Liu, Li Fu, Zhongsheng Tong
Oncotarget.2016; 7(32): 52450. CrossRef
Radiotherapy did not increase thyroid cancer risk among women with breast cancer: A nationwide population‐based cohort study
Li‐Min Sun, Cheng‐Li Lin, Ji‐An Liang, Wen‐Sheng Huang, Chia‐Hung Kao
International Journal of Cancer.2015; 137(12): 2896. CrossRef
A Possible Association Between Thyroid Cancer and Breast Cancer
Jee Hyun An, Yul Hwangbo, Hwa Young Ahn, Bhumsuk Keam, Kyu Eun Lee, Wonshik Han, Do Joon Park, In Ae Park, Dong-Young Noh, Yeo-Kyu Youn, Bo Youn Cho, Seock-Ah Im, Young Joo Park
Thyroid.2015; 25(12): 1330. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Metachronous Double Primary Cancer after Treatment of Breast Cancer

Cancer Res Treat. 2015;47(1):64-71. Published online October 27, 2014

DOI: https://doi.org/10.4143/crt.2013.215

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Metachronous Double Primary Cancer after Treatment of Breast Cancer

Fig. 1. Kaplan-Meier survival curve of metachronous double primary cancer of breast cancer patients from the diagnosis of second cancer (n=108).

Fig. 1.

Metachronous Double Primary Cancer after Treatment of Breast Cancer

Age (yr)	With second cancer		Without second cancer
Age (yr)	Male	Female	Male	Female
11-20	-	-	0	3 (0.1)
21-30	-	-	0	61 (2.4)
31-40	0	6 (5.6)	1 (7.1)	354 (14.0)
41-50	0	43 (40.2)	1 (7.1)	914 (36.1)
51-60	0	35 (32.7)	4 (28.6)	675 (26.6)
61-70	1	16 (15.0)	6 (42.9)	360 (14.2)
71-80	0	6 (5.6)	2 (14.3)	144 (5.7)
81-90	0	1 (0.9)	0	24 (0.9)
Total	1	107	14	2,535

Cancer type	Double primary cancer
Cancer type	No.	Age (yr)
Thyroid cancer	45 (41.7)	52.0±7.3 (41.6-73.9)
Stomach cancer	16 (14.8)	65.4±4.7 (46.8-74.3)
Endometrial cancer	10 (9.3)	55.3±13.6 (39.3-83.3)
Cervical cancer	7 (6.5)	48.9±15.7 (35.0-72.6)
Lung cancer	5 (4.6)	65.0±5.3 (58.4-72.1)
Rectal cancer	4 (3.7)	60.7±12.3 (44.6-74.6)
Acute myelocytic leukemia	4 (3.7)	50.0±6.3 (48.1-61.8)
Colon cancer	3 (2.8)	65.4±4.7 (59.0-68.1)
Biliary cancer	3 (2.8)	68.7±12.8 (60.5-85.7)
Ovarian cancer	3 (2.8)	57.3±3.3 (54.4-61.0)
Hepatocellular carcinoma	2 (1.9)	73.8±3.3 (71.5-76.2)
Bladder cancer	2 (1.9)	69.3±11.8 (61.0-77.6)
Nasopharyngeal cancer	1 (0.9)	39.5
Renal cell carcinoma	1 (0.9)	49.5
Acute lymphocytic leukemia	1 (0.9)	48.2
Total	108	55.9±10.3 (35.0-85.7)

Diagnostic period (yr)	No.
< 1	13
1-3	28
3-5	19
5-7	14
7-9	21
9-1	9
11-13	2
13-15	1
15-17	1
Total	108

Cancer type	Diagnostic period (mo)
Thyroid cancer	48.9±33.9 (7.1-121.8)
Stomach cancer	71.5±41.5 (6.9-129.3)
Endometrial cancer	60.5±37.4 (8.5-107.9)
Cervical cancer	61.3±60.9 (8.5-180.2)
Lung cancer	89.1±45.9 (21.9-142.3)
Rectal cancer	53.1±58.4 (8.3-135.2)
Acute myelocytic leukemia	21.1±11.0 (11.0-36.3)
Colon cancer	51.9±63.2 (9.5-124.5)
Biliary cancer	51.3±29.5 (24.2-82.7)
Ovarian cancer	56.5±38.4 (13.2-90.4)
Hepatocellular carcinoma	86.4±49.4 (51.5-121.3)
Bladder cancer	129.65±45.5 (97.5-161.8)
Nasopharyngeal cancer	69.7
Renal cell carcinoma	84.7
Acute lymphocytic leukemia	26.4
Total	58.4±41.2 (6.9-180.2)

Cancer type	After 5 years	After 10 years	Total
Thyroid cancer	17 (37.8)	1 (2.2)	45
Stomach cancer	9 (56.3)	2 (12.5)	6
Endometrial cancer	5 (50.0)	-	10
Cervical cancer	3 (42.9)	1 (14.3)	7
Lung cancer	4 (80.0)	2 (40.0)	5
Rectal cancer	1 (25.0)	1 (25.0)	4
Acute myelocytic leukemia	-	-	4
Colon cancer	1 (33.3)	1 (33.3)	3
Biliary cancer	1 (33.3)	-	3
Ovarian cancer	2 (66.7)	-	3
Hepatocellular carcinoma	1 (50.0)	1 (50.0)	2
Bladder cancer	2 (100)	1 (50.0)	2
Nasopharyngeal cancer	1 (100)	-	1
Renal cell carcinoma	1 (100)	-	1
Acute lymphocytic leukemia	-	-	1
Total	48 (44.4)	10 (9.3)	108

Cancer type	Relative risk	95% CI
Nasopharyngeal cancer	6.30	0.15-271.59
Endometrial cancer	4.78	1.66-13.79
Acute myelocytic leukemia	2.61	0.70-9.81
Stomach cancer	2.61	1.68-4.06
Bladder cancer	2.37	0.39-14.40
Thyroid cancer	1.95	1.37-2.79
Ovarian cancer	1.05	0.33-3.34
Biliary cancer	1.04	0.33-3.28
Cervical cancer	0.94	0.45-1.95
Acute lymphocytic leukemia	0.88	0.13-5.94
Lung cancer	0.87	0.40-1.91
Renal cell carcinoma	0.81	0.12-5.24
Rectal cancer	0.55	0.23-1.32
Colon cancer	0.35	0.14-0.90
Hepatocellular carcinoma	0.34	0.11-1.08
Total	0.95	0.79-1.15

Cancer type	No.	5-Year survival rate (%)^a)	Median±SD (mo)	95% CI
Thyroid cancer	45	100	-	-
Stomach cancer	16	61.9	64.4±12.4	40.2-88.7
Endometrial cancer	10	80.0	150.3±22.8	105.6-195.0
Cervical cancer	7	83.3	128.4±29.8	69.9-186.9
Lung cancer	5	22.2	18.0±4.4	9.3-26.7
Rectal cancer	4	66.7	85.9±26.8	33.5-138.4
Acute myelocytic leukemia	4	0	3.2±1.6	0.1-6.3
Colon cancer	3	100	121.4	-
Biliary cancer	3	0	14.8±6.1	2.9-26.7
Ovarian cancer	3	0	36.6±10.9	15.3-57.9
Hepatocellular carcinoma	2	0	10.4±3.8	3.0-17.8
Bladder cancer	2	-	6.8	-
Nasopharyngeal cancer	1	-	-	-
Renal cell carcinoma	1	-	-	-
Acute lymphocytic leukemia	1	0	-	-
Total	108	72.3	123.9±11.2	102.0-145.9

Table 1. Sex and age distribution at the time of diagnosis of breast cancer with or without second primary cancer

Values are presented as number (%).

Table 2. Cancer type and mean age distribution of metachronous double primary cancer in breast cancer patients

Values are presented as number (%) or mean±standard deviation (range).

Table 3. Diagnostic period of metachronous double primary cancer in patients with breast cancer

Values are presented as number (%).

Table 4. Mean diagnostic period of metachronous double primary cancer in breast cancer patients

Values are presented as mean±standard deviation (range).

Table 5. Diagnosis of metachronous double primary cancer 5 years and 10 years after diagnosis of breast cancer

Values are presented as number (%).

Table 6. Relative risk of metachronous double primary cancer in breast cancer patients

CI, confidence interval.

Table 7. Median survival after diagnosis of metachronous double primary cancer in patients with breast cancer